⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Official Title: A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)

Study ID: NCT01108445

Interventions

Everolimus
Sunitinib

Study Description

Brief Summary: To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.

Detailed Description: This will be an international (USA, Canada, and UK) open-label, outpatient, multicenter, randomized study of treatment with RAD001 (everolimus (Afinitor®) or sunitinib (Sutent®) in subjects with mRCC and non-clear cell histology. Special emphasis is placed on papillary and chromophobe histologies while sarcomatoid clear cell variants, medullary, and collecting duct carcinomas will be excluded (see eligibility). Subjects may continue receiving study drugs until disease progression, unacceptable toxicities, or withdrawal of consent, for a maximum of 24 months. Continuation of study assigned treatment will be allowed beyond 24 months at the discretion of the sponsor. Stratification variables will include histology (papillary vs. chromophobe) and Motzer risk criteria (0, 1-2, and 3). Tumor progression will be assessed locally and by independent review, in strict accordance with Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria measured every 12 weeks. At the time of progression, subjects will be taken off study other than simple administrative mortality follow-up. Primary pathologic samples and plasma/urine angiokine levels at baseline and over time will be collected and stored centrally for biomarker analysis.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of Chicago, Chicago, Illinois, United States

Indiana University Melvin and Bran Simon Cancer Center, Indianapolis, Indiana, United States

Karmanos Cancer Institute/Wayne State University, Detroit, Michigan, United States

Washington Univ in St. Louis-School of Medicine, Saint Louis, Missouri, United States

Duke Univeristy Medical Center, Durham, North Carolina, United States

Cleveland Clinic, Cleveland, Ohio, United States

Oregon Health & Science University, Portland, Oregon, United States

SCRI, Nashville, Tennessee, United States

The Vanderbilt Clinic, Henry-Joyce Cancer Center, Nashville, Tennessee, United States

BC Cancer Agency, Vancouver, British Columbia, Canada

CancerCare Manitoba, Med Onc, Dept Hem and Onc, Winnipeg, Manitoba, Canada

London Health Sciences Center, London, Ontario, Canada

Cambridge Cancer Trials Centre, Cambridge, England, United Kingdom

The Royal Marsden NHS, London, England, United Kingdom

The Christie Hospital NHS, Manchester, England, United Kingdom

Weston Park Hospital, Sheffield, England, United Kingdom

Churchill Hospital, Headington, Oxford, United Kingdom

Beatson West Scotland Cancer Centre, Glasgow, Scottland, United Kingdom

Contact Details

Name: Andrew Armstrong, MD, ScM

Affiliation: Duke University

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: